Luye Pharma Group has been growing earnings at an average annual rate of 12.3%, while the Pharmaceuticals industry saw earnings growing at 8.3% annually. Revenues have been growing at an average rate of 3.7% per year. Luye Pharma Group's return on equity is 3.8%, and it has net margins of 9.8%.
Key information
12.27%
Earnings growth rate
8.36%
EPS growth rate
Pharmaceuticals Industry Growth
7.33%
Revenue growth rate
3.74%
Return on equity
3.84%
Net Margin
9.81%
Last Earnings Update
31 Dec 2025
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Luye Pharma Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
DB:LUP Revenue, expenses and earnings (CNY Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Dec 25
6,308
619
2,506
0
30 Sep 25
6,238
508
2,549
0
30 Jun 25
6,168
397
2,593
0
31 Mar 25
6,115
434
2,496
0
31 Dec 24
6,061
472
2,398
0
30 Sep 24
6,187
621
2,413
0
30 Jun 24
6,314
770
2,428
0
31 Mar 24
6,228
652
2,564
0
31 Dec 23
6,143
533
2,700
0
30 Sep 23
6,089
495
2,705
0
30 Jun 23
6,035
458
2,711
0
31 Mar 23
6,008
531
2,557
0
31 Dec 22
5,982
605
2,403
0
30 Sep 22
5,541
190
2,365
0
30 Jun 22
5,099
-224
2,327
0
31 Mar 22
5,150
-179
2,301
0
31 Dec 21
5,200
-134
2,276
0
30 Sep 21
5,365
210
2,196
0
30 Jun 21
5,529
554
2,116
0
31 Mar 21
5,534
630
2,151
0
31 Dec 20
5,540
707
2,185
0
30 Sep 20
5,864
955
2,302
0
30 Jun 20
6,189
1,204
2,419
0
31 Mar 20
6,273
1,300
2,491
0
31 Dec 19
6,358
1,396
2,564
0
30 Sep 19
6,229
1,434
2,506
0
30 Jun 19
6,101
1,472
2,448
0
31 Mar 19
5,637
1,388
2,287
0
31 Dec 18
5,173
1,303
2,127
0
30 Sep 18
4,671
1,231
1,957
0
30 Jun 18
4,168
1,159
1,787
0
31 Mar 18
3,991
1,070
1,753
0
31 Dec 17
3,815
981
1,718
0
30 Sep 17
3,547
917
1,629
0
30 Jun 17
3,280
852
1,539
0
31 Mar 17
3,099
872
1,464
0
31 Dec 16
2,918
892
1,389
0
30 Sep 16
2,784
843
1,310
0
30 Jun 16
2,649
794
1,232
0
31 Mar 16
2,606
774
1,190
0
31 Dec 15
2,563
755
1,149
0
30 Sep 15
2,481
732
1,037
0
30 Jun 15
2,400
710
924
0
Quality Earnings: LUP has high quality earnings.
Growing Profit Margin: LUP's current net profit margins (9.8%) are higher than last year (7.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: LUP's earnings have grown by 12.3% per year over the past 5 years.
Accelerating Growth: LUP's earnings growth over the past year (31.1%) exceeds its 5-year average (12.3% per year).
Earnings vs Industry: LUP earnings growth over the past year (31.1%) exceeded the Pharmaceuticals industry 12.5%.
Return on Equity
High ROE: LUP's Return on Equity (3.8%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/04/30 20:44
End of Day Share Price
2026/04/30 00:00
Earnings
2025/12/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Luye Pharma Group Ltd. is covered by 17 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.